Natco Pharma Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Natco Pharma Ltd. on BSE

Search Inside the pdf :

Natco Pharma Ltd.

09 Apr 2025

803.95

3.67%

Corp. Note

Natco Pharma Ltd - 524816 - Format of the Initial Disclosure to be made by an …

BSE India

Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyNatco Pharma Ltd 2CIN NO.L24230TG1981PLC003201 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY AA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)ICRA LIMITED 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkNSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: CH VENKAT RAMESH Designation: COMPANY SECRETARY AND COMPLIANCE OFFICER EmailId: venkatramesh.ch@natcopharma.co.in Name of the Chief Financial Officer: S V V N APPA RAO Designation: CHIEF FINANCIAL OFFICER EmailId: svvn@natcopharma.co.in Date: 09/04/2025 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

pdf

Natco Pharma Ltd.

08 Apr 2025

803.95

3.67%

Company Update

Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Legal Update regarding RISDIPLAM launch in India

pdf

Natco Pharma Ltd.

03 Apr 2025

803.95

3.67%

Company Update

Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Change in Management

BSE India

Announcement under Regulation 30 (LODR) Regulations, 2015

pdf

Natco Pharma Ltd.

31 Mar 2025

803.95

3.67%

Company Update

Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Change in Management

BSE India

Disclosure under regulation 30 of the SEBI (LODR) Regulations, 2015

pdf

Natco Pharma Ltd.

29 Mar 2025

803.95

3.67%

SAST

Natco Pharma Ltd - 524816 - Closure of Trading Window

BSE India

Closure of Trading Window

pdf

Natco Pharma Ltd.

27 Mar 2025

803.95

3.67%

SAST

Natco Pharma Ltd - 524816 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

BSE India

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sanjay Nannapaneni

pdf

Natco Pharma Ltd.

21 Mar 2025

803.95

3.67%

SAST

Natco Pharma Ltd - 524816 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

BSE India

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Rajeev Nannapaneni & Venkata Satya Swathi Kantamani

pdf

Natco Pharma Ltd.

03 Mar 2025

803.95

3.67%

SAST

NATCO PHARMA LTD. - 524816 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011

BSE India

The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Satya Vani Nannapaneni & Sanjay Nannapaneni

pdf

Natco Pharma Ltd.

03 Mar 2025

803.95

3.67%

Company Update

NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Change in Management

BSE India

Mr. Bhimrao Dattu Jadhav has been appointed as Senior Vice President - Operations (formulations) for Pharma Division - Kothur of the Company w.e.f. 3rd March, 2025

pdf